Table 1 Comparison of clinical manifestations and laboratory features between SLC22A3 hypomethylated and hypermethylated AML patients

Sex, male/female

38/27

31/17

22/15

12/10

Median age, years (range)

58 (18–85)

55 (18–85)

62 (18–85)

59 (18–79)

Median WBC, × 10⁹/L (range)

19.9 (0.9–528.0)

20.1 (0.4–165.8)

33.9 (1.2–528)

23.7 (0.9–135.4)

Median hemoglobin, g/L (range)

84 (32–133)

76 (34–144)

87 (32–123)

76 (47–144)

Median platelets, × 10⁹/L (range)

49 (9–447)

36 (5–264)

52 (9–234)

44 (7–148)

BM blasts, % (range)

50.8 (20.0–99.0)

60.5 (21.5–94.5)

58.5 (21.5–99)

58.0 (21.5–93)

FAB

 M0

0 (0%)

2 (4.2%)

0 (0%)

1 (4.3%)

 M1

5 (7.7%)

4 (8.3%)

3 (7.9%)

1 (4.3%)

 M2

31 (47.7%)

24 (50%)

16 (42.1%)

9 (39.1%)

 M3

–

–

–

–

 M4

19 (29.2%)

7 (14.6%)

11 (28.9%)

4 (17.4%)

 M5

7 (10.8%)

9 (18.8%)

5 (13.2%)

6 (26.1%)

 M6

3 (4.6%)

2 (4.2%)

2 (5.3%)

1 (4.3%)

Cytogenetic classification

0.616

 Favorable

5 (7.7%)

7 (14.6%)

 Intermediate

44 (67.7%)

31 (64.6%)

 Adverse

13 (20%)

9 (18.8%)

 No data

3 (4.6%)

1 (2.1%)

Karyotype

 Normal

37 (56.9%)

22 (45.8%)

 t(8;21)

5 (7.7%)

6 (12.5%)

 t(16;16)

0 (0%)

1 (2.1%)

 t(v; 11q23)

2 (3.1%)

3 (6.3%)

 -5/5q-

0 (0%)

1 (2.1%)

 t(9;22)

1 (1.5%)

1 (2.1%)

 -7/7q-

3 (4.6%)

1 (2.1%)

 Complex

5 (7.7%)

6 (12.5%)

 Other

1 (1.5%)

1 (2.1%)

 No data

11 (16.9%)

6 (12.5%)

Gene mutation

 CEBPA ( ±)

2/54

9/29

1/30

3/14

 NPM1 ( ±)

8/49

6/32

7/25

5/12

 FLT3-ITD ( ±)

4/52

3/35

4/27

2/15

 c-KIT ( ±)

3/53

2/36

2/29

0/17

 N/K-RAS ( ±)

4/52

7/31

2/29

5/12

 IDH1/2 ( ±)

2/54

3/35

1/30

3/14

 DNMT3A ( ±)

3/53

2/36

3/28

2/15

 U2AF1 ( ±)

1/55

2/36

1/30

1/16

 SRSF2 ( ±)

3/53

1/37

2/29

0/17

 SETBP1 ( ±)

1/55

1/37

0/31

1/16